Clinical trial

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

NCT00694551

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Peptide Vaccine Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Poly IC-LC Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-12-02

PhaseNA

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

Peptide VaccineBIOLOGICAL

Poly IC-LCDRUG

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

National Institutes of Health (NIH)collaborator

Mapped research locations

TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00694551 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.